Summary

• In ROCKET AF, nonvalvular atrial fibrillation was defined as atrial fibrillation in the absence of mitral valve stenosis or prosthetic heart valve. Specifically, patients were excluded if they had hemodynamically significant mitral valve stenosis or prosthetic heart valve; however, patients with mitral valve repair such as annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty were permitted.^1,2

CLINICAL STUDIES

The ROCKET AF (Rivaroxaban, Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial evaluated the efficacy and safety of XARELTO and warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation at moderate-to-high risk for stroke.²

In ROCKET AF, nonvalvular atrial fibrillation was defined as atrial fibrillation in the absence of mitral valve stenosis or prosthetic heart valve. Specifically, patients were excluded if they had hemodynamically significant mitral valve stenosis or prosthetic heart valve; however,      patients with mitral valve repair such as annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty were permitted.^1,2

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 18 September 2024.